证券代码：301331 证券简称：恩威医药 公告编号：2026-002 恩威医药股份有限公司 股东询价转让计划书 股东成都恩威投资（集团）有限公司保证向恩威医药股份有限公司提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对真实性、准确性和 完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次拟参与恩威医药股份有限公司（以下简称"公司"）首次公开发行前 （以下简称"首发前"）股东询价转让的股东为成都恩威投资（集团）有限公司（以 下简称"出让方"）； 公司总股本为102,891,887股，其中公司回购专用证券账户持有1,055,326 股。本次出让方拟转让股份总数为 4,000,000 股，占公司总股本的比例为 3.89%， 占剔除公司已回购股份后的总股本的比例为 3.93% ； 本次询价转让不通过集中竞价交易或大宗交易方式进行，不属于通过二 级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投 资者。 一、 拟参与转让的股东情况 (一) 出让方的名称、持股 ...

本报讯(记者蒙婷婷)1月20日晚间，恩威医药（301331）股份有限公司(以下简称"恩威医药")发布2025年 度业绩预告，2025年1月至12月，公司预计实现归属于上市公司股东的净利润5650万元至6650万元，同 比预增50.68%至77.35%；预计实现归属于上市公司股东的扣除非经常性损益后的净利润4900万元至 5900万元，同比预增41.09%至69.88%，业绩呈现稳步增长态势。 就2025年业绩的快速增长，公司预告明确核心驱动因素为两大方面：一是主营业务收入稳步攀升，直接 带动净利润规模扩大；二是股权激励计划相关成本摊销金额减少，有效优化了利润结构。此外，报告期 内非经常性损益对公司净利润的预计影响金额约为750万元，为业绩增长提供了一定补充。 恩威医药核心业务聚焦中成药、化学药及健康私护用品的研发、生产及销售，深耕妇科产品、儿科用 药、呼吸系统用药及健康私护用品等领域。其中，妇科外用洗液"洁尔阴洗液"作为公司拳头产品，市场 认可度高、品牌影响力深厚。在此基础上，公司持续丰富产品矩阵，拓展出软膏、栓剂、胶囊剂、泡腾 片等剂型以及抑菌洗液等消毒产品，通过自主研发、联合研发、品种收购等多重模式深耕妇 ...

近日，恩威医药披露2025年度业绩预告，预计2025年归母净利润为5650万元至6650万元，同比增长50.68%至77.35%。 2025年业绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少。 （恩威医药公告） ...

Core Viewpoint - The company, Enwei Pharmaceutical, anticipates a significant increase in net profit for the year 2025, projecting a rise of over 50% compared to the previous year [2][3]. Group 1: Performance Forecast - The performance forecast period is set from January 1, 2025, to December 31, 2025 [1]. - The expected net profit is projected to be positive and to increase by more than 50% [2]. Group 2: Communication with Auditors - The data related to the performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by the accounting firm [2]. - The company has had preliminary discussions with the accounting firm regarding the performance forecast, and there are no significant disagreements [2]. Group 3: Reasons for Performance Change - The primary reason for the anticipated increase in performance for 2025 is attributed to growth in main business revenue, which will lead to an increase in net profit, along with a reduction in the amortization costs of the equity incentive plan [3]. Group 4: Non-Recurring Gains - It is estimated that non-recurring gains and losses will impact net profit by approximately 7.5 million yuan [4]. Group 5: Additional Information - The performance forecast data is preliminary, and detailed financial data will be disclosed in the annual report for 2025 [5].

Group 1: New Stock Offerings - Medela's new stock offering has a subscription code of 920119, with an issue price of 41.88 yuan per share and a price-to-earnings ratio of 14.99 times, allowing a maximum subscription limit of 720,000 shares per account [2] Group 2: Fiscal Policy and Economic Measures - The Ministry of Finance will continue to implement a more proactive fiscal policy, aiming for increased total spending, improved structure, better efficiency, and stronger momentum, with necessary levels of fiscal deficit, total debt, and spending maintained through 2026 [3] - The Ministry of Finance has optimized the personal consumption loan interest subsidy policy, including credit card installment payments, removing restrictions on certain consumption areas, allowing all consumer loans to enjoy interest subsidies [3] - Starting April 1, 2026, export tax rebates for photovoltaic products will be canceled, and electronic product export tax rebates will be phased out over two years, promoting efficient resource use and guiding rational industrial structure adjustments [3] - Tax and fee preferential policies for community services such as elderly care, childcare, and housekeeping will continue, benefiting institutions providing these services [3] Group 3: Commodity Market Adjustments - The Shanghai Futures Exchange will adjust margin ratios and price fluctuation limits for futures contracts of copper, gold, and other commodities starting January 22, 2026 [4] - Domestic gasoline and diesel prices will increase by 85 yuan per ton due to rising international oil prices, marking the first price hike in 2026, with an average increase of 0.07 yuan per liter for 92 and 95 gasoline and 0 diesel [4] - Shanghai has released an action plan to enhance the linkage between spot and futures markets for non-ferrous metals, aiming to expand the international influence of "Shanghai prices" [4] Group 4: Company Earnings Forecasts - Huicheng Environmental Protection plans to increase its shareholding by 25 million to 50 million yuan [7] - JianTou Energy expects a net profit increase of approximately 253.38% year-on-year for 2025 [7] - Hikvision's performance report indicates a year-on-year growth of 18.46% in net profit attributable to shareholders for 2025 [7] - Longzi Co. anticipates a net profit increase of 245.25% to 302.8% year-on-year for 2025 [7] - Zhaoyan New Drug expects a net profit increase of 214% to 371% year-on-year for 2025 [8] - Huachen Equipment forecasts a net profit increase of 193.64% to 242.04% year-on-year for 2025 [8] - Qianyuan Power anticipates a net profit increase of 160% to 190% year-on-year for 2025 [8] - Jin Fang Energy expects a net profit increase of 123.97% to 193.7% year-on-year for 2025 [8] - Other companies such as Zhongfu Industrial, Batian Co., and Dongwei Technology also project significant year-on-year profit increases for 2025, ranging from 50% to over 300% [8][9]

（编辑 袁冠琳） 证券日报网讯 1月20日，恩威医药发布2025年度业绩预告称，公司预计2025年度归属于上市公司股东的 净利润为5，650万元～6，650万元，比上年同期3，749.75万元增长50.68%～77.35%。 ...

恩威医药(301331.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润5650万元至6650 万元，同比增长50.68%至77.35%;扣除非经常性损益后的净利润4900万元至5900万元，同比增长41.09% 至69.88%。 ...

新京报贝壳财经讯1月20日，恩威医药（301331）公告，预计2025年度净利润为5650万元至6650万元， 同比增长50.68%～77.35%。报告期内，预计非经常性损益对净利润的影响金额约为750万元。2025年业 绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少所致。 ...

恩威医药（301331）(301331.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润5650 万元至6650万元，同比增长50.68%至77.35%;扣除非经常性损益后的净利润4900万元至5900万元，同比 增长41.09%至69.88%。 ...

1、2025年业绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少所 致。2、报告期内，预计非经常性损益对净利润的影响金额约为750万元。 格隆汇1月20日丨恩威医药(301331.SZ)公布，预计2025年归属于上市公司股东的净利润5,650万元～ 6,650万元，比上年同期增长50.68%～77.35%，扣除非经常性损益后的净利润4,900万元～5,900万元，比 上年同期增长41.09%～69.88%。 ...